Anticancer Activity of Calotropis procera by Molecular Docking Analysis

Year : 2024 | Volume : 02 | Issue : 01 | Page : 01 07
    By

    Krithika Vasanth Naik,

  • Nilofar Khan,

  1. Resesarch Intern, BioNome for Genomics and Bioinformatics Solution, Bengaluru, Karnataka, India
  2. Resesarch Intern, BioNome for Genomics and Bioinformatics Solution, Bengaluru, Karnataka, India

Abstract

Cyclin-dependent kinase 2 (CDK2) is a protein synthesized by Calotropis procera. It is known to be responsible for causing cancer in the human body. Studies have presented the significance of the phytochemicals to inhibit the CDK2 protein. Adsorption, distribution, metabolism, and excretion (Swiss ADME) and PubChem were the pharmacological tools which were used to check molecular weight, which should be less than 500D, acceptors less than 10, and donors less than 5, Log P less than 5 and gastrointestinal (GI) absorption should be high and Blood Bank Barrier (BBB) is also identified. If the drug-likeness is absent and has 2 violations then there will be no drug discovery. Using PubChem, the ligands were searched and the Simplified molecular-input line-entry system (SMILES) was copied and pasted to the list of smiles box in Swiss ADME and ran the process. From that, we come to know the molecular weight, acceptors, donors log p values, etc. By using a protein data bank (PDB) we got a PDB ID for CDK2 protein, i.e., 5NEV. Later 3d ligand binding site and active site prediction for protein was identified. The total ligands used here are 5 and they are calotropagenin, anthraquinone, flavonoid (ternatin), coumarin, and cannogenin. Then all the ligands were cleaned using Marvin’s sketch. Energy minimization of protein was done by using the Swiss PDB viewer and then the PyRx tool (Visualization tool) was used to check the least binding affinity of the ligands. From the 5 ligands one which has the least binding affinity is taken for the docking process. Here, the ligand which is having least binding affinity is anthraquinone which is bound to the CDK2 protein. And later the docking visualization was performed using Biovia Discovery Studio and AutoDock Tools-1.5.6.

Keywords: Cyclin-dependent kinase 2 protein, anthraquinone, Lipinski rule, Ramachandran plot, anticancer activity

[This article belongs to International Journal of Biochemistry and Biomolecule Research ]

How to cite this article:
Krithika Vasanth Naik, Nilofar Khan. Anticancer Activity of Calotropis procera by Molecular Docking Analysis. International Journal of Biochemistry and Biomolecule Research. 2024; 02(01):01-07.
How to cite this URL:
Krithika Vasanth Naik, Nilofar Khan. Anticancer Activity of Calotropis procera by Molecular Docking Analysis. International Journal of Biochemistry and Biomolecule Research. 2024; 02(01):01-07. Available from: https://journals.stmjournals.com/ijbbr/article=2024/view=168776


Browse Figures

References

  1. Li Y, Zhang J, Gao W, Zhang L, Pan Y, Zhang S, Wang Y. Insights on structural characteristics and ligand binding mechanisms of CDK2. Int J Mol Sci. 2015 Apr 24;16(5):9314–40. doi: 10.3390/ijms16059314. PMID: 25918937; PMCID: PMC4463590.
  2. Guedes IA, de Magalhães CS, Dardenne LE. Receptor-ligand molecular docking. Biophys Rev. 2014 Mar;6(1):75-87. doi: 10.1007/s12551-013-0130-2. Epub 2013 Dec 21. PMID: 28509958; PMCID: PMC5425711.
  3. Bhowmick S, AlFaris NA, ALTamimi JZ, ALOthman ZA, Aldayel TS, Wabaidur SM, Islam MA. Screening and analysis of bioactive food compounds for modulating the CDK2 protein for cell cycle arrest: multi-cheminformatics approaches for anticancer therapeutics. J Mol Struct. 2020;1216. doi: 10.1016/j.molstruc.2020.128316.
  4. Hermanson GT. Bioconjugate Techniques. Amsterdam: Academic Press; 2013. doi: 10.1016/C2009-0-64240-9.
  5. Panche AN, Diwan AD, Chandra SR. Flavonoids: An overview. J Nutr Sci. 2016;5. doi: 10.1017/jns.2016.41. PubMed PMID: 28620474.
  6. Lacy A, O’Kennedy R. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des. 2004;10(30):3797-811. doi: 10.2174/1381612043382693. PMID: 15579072.
  7. Hanna AG, Shalaby NMM, Morsy NAM, Simon A, Tóth G, Malik S, Duddeck H. Structure of a calotropagenin-derived artifact from Calotropis procera. Magn Reson Chem. 2002;40:599–602. doi: 10.1002/mrc.1057.
  8. Madhulika B, Vikas S. Anticancer activity of Arka (Calotropis procera) on HCT-15 cancer cell line. Int J Med Sci. 2010;2(2):152–4.
  9. Nalini S, Nandini S, Suresh GS, Melo JS, Neelagund SE, NaveenKumar HN, et al. An electrochemical perspective assay for anticancer activity of Calotropis procera against glioblastoma cell line (LN-18) using carbon nanotubes-graphene nano-conglomerate as a podium. Adv Mater Lett. 2016;7(12):1003–9. doi: 10.5185/amlett.2016.6395.
  10. Choedon T, Mathan G, Arya S, Kumar VL, Kumar V. Anticancer and cytotoxic properties of the latex of Calotropis procera in a transgenic mouse model of hepatocellular carcinoma. World J Gastroenterol. 2006;12:2517–22. doi: 10.3748/wjg.v12.i16.2517. PubMed PMID: 16688796.
  11. Al-Qahtani MAM, Abul FM, Abou-Tarboush FM, Al-Anazi KM, Al-Harbi NO, Ali MA, et al. Anticancer effects of Calotropis procera latex extract in mcf-7 breast cancer cells. Pharmacogn Mag. 2020;16(71):550–6. doi: 10.4103/pm.pm_156_20.
  12. Tripathi P, Ghosh S, Talapatra SN. Bioavailability prediction of phytochemicals present in Calotropis procera (Aiton) R. Br. by using Swiss-ADME tool. World Sci News. 2019;131:147–63.
Regular Issue Subscription Original Research
Volume 02
Issue 01
Received 09/05/2024
Accepted 27/05/2024
Published 23/08/2024
Publication Time 106 Days
500

Login


My IP

PlumX Metrics